We Claim:

~~1. A process for preparing N-[2-[2-(4-Chlorophenyl)-4-thiazolyl] ethyl]-butanamide, comprising the steps of:~~

~~a. refluxing 4- chlorobenzathiomide with a suitable reagent for esterification to obtain an ester;~~

~~b. reducing the ester to obtain a reduced intermediate;~~

~~c. reacting the reduced intermediate (alcohol or aldehyde) with a suitable reagent to obtain a thiazole~~

~~d. optionally reducing the intermediate as obtained with a reducing agent or reacting the said intermediate with a suitable reagent to obtain [2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide.~~

~~2. The process as claimed in claim 1, comprising the steps of:~~

~~(1) Refluxing 4- chlorobenzathiomide with the adding chloroacetoacetate to obtain Ethyl 2-(2-(4-chlorophenyl)thiazol-4-yl)acetate;~~

~~(2) Reducing ethyl 2-(2-(4-chlorophenyl)thiazol-4-yl)acetate with the addition of sodium borohydride to obtain 2-(2-(4-chlorophenyl)thiazol-4-yl)ethan-1-ol;~~

~~(3) Reacting 2-(2-(4-chlorophenyl)thiazol-4-yl)ethan-1-ol as obtained in step (2) with methylsulphonyl chloride and then with NaN_3 to obtain 4-(2-azidoethyl)-2-(4-chlorophenyl) thiazole; and~~

~~(4) Reducing 4-(2-azidoethyl)-2-(4-chlorophenyl) thiazole as obtained in step (4) with triphenyl phosphine to obtain [2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide.~~

~~3.~~1.A process for preparing N-[2-[2-(4-Chlorophenyl)-4-thiazolyl] ethyl]-butanamide, ~~The process as claimed in claim 1~~ comprising the steps of:

(1) Refluxing 4- chlorobenzathiomide adding Ethyl 3-bromo-2-oxopropanoate to obtain Ethyl 2-(2-(4-chlorophenyl)thiazol-4-yl)acetate;

(2) Reducing ethyl 2-(2-(4-chlorophenyl)thiazol-4-yl)acetate as obtained in step (1) with the addition of DIBAL-H solution to obtain 2-(4-chlorophenyl)thiazole-4-carbaldehyde;

(3) Reacting 2-(4-chlorophenyl)thiazole-4-carbaldehyde as obtained in step (2) was then reacted with nitromethane, pyrrolidine and acetic acid respectively;

(4) Reducing the 2-(4-chlorophenyl)-4-(2-nitrovinyl) thiazole obtained from step(3) with Pd to obtain 2-(4-chlorophenyl)thiazole-4-yl)ethane-1-~~aminen~~amine;

(5) Reacting 2-(4-chlorophenyl)thiazole-4-yl)ethane-1-~~aminen~~ amine as obtained in step (4) with triethyl amine and further with butyryl chloride to obtain [2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide.

~~4.~~2.A pharmaceutical formulation comprising N-[2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide or pharmaceutically acceptable salts thereof, as the active compound wherein the strength of the said active compound is in the range of 0.1% to 90% along with suitable excipients in an acceptable range.

~~5.~~3.The pharmaceutical formulation as claimed in claim ~~4~~2, wherein the strength of the active compound or pharmaceutically acceptable salts thereof, is preferably in the range of 0.1% to 20% along with suitable excipients in an acceptable range.

~~6.~~4.The pharmaceutical formulation as claimed in claim ~~4~~ 2 for topical application comprising N-[2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide or pharmaceutically acceptable salts thereof, in the range of 0.1 to 40 wt%, dissolved in a solvent added in an amount in the range of 8-25wt%, along with a gelling agent in an amount in the range of 45-65 wt% and a permeation enhancer which is in an amount in the range of 10 -25 wt%.

~~7.~~5.The pharmaceutical formulation as claimed in claim ~~6~~ 4 optionally comprising a stiffening agent, emulsifying agent, gelling agent, humectant, preservative, antioxidant, chelating agent, buffer and a suitable solvent.

~~8.~~6.The pharmaceutical formulation as claimed in claim ~~6~~4, wherein the solvent is selected from a group consisting of purified water, hexylene glycol, propylene glycol, oleyl alcohol and propylene carbonate.

~~9.~~7.The pharmaceutical formulation as claimed in claim ~~6~~4, wherein the gelling agent is selected from a group consisting of carbomer, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, guar gum, hydroxypropyl

cellulose, hydroxypropyl methyl cellulose, gelatin, polyethylene oxide, alginic acid and Sodium alginate.

~~10.~~8. The pharmaceutical formulation as claimed in claim ~~6~~4, wherein the permeation enhancer is selected from a group consisting of propylene glycol, ethanol, isopropyl alcohol, oleic acid and polyethylene glycol.

~~11.~~9. Use of N-[2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of skin autoimmune diseases and pigmentation disorders selected from the group consisting of Vitiligo, Psoriasis, Atopic dermatitis and eczema, lichen-planus, Scleroderma, Pemphigus, Bullous, Epidermolysis bullosa, Systemic lupus erythematosus, dermatomyositis, and Alopecia areata.

~~12.~~10. The use as claimed in claim ~~11~~9, wherein the skin autoimmune disease is vitiligo.

~~13.~~11. The formulation as claimed in claim ~~4~~2, wherein the formulation is an oral, parenteral, topical, transdermal, intravenous, rectal, sublingual, nasal, and rectal formulation.

~~14.~~12. The formulation as claimed in claim ~~4~~2, wherein the formulation is in the form of a solution, gel, ointment, cream, lotion, spray or foam.

~~15.~~13. Use of N-[2-[2-(4-chlorophenyl)-4-thiazolyl] ethyl]-butanamide or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treatment of an autoimmune disease in a subject.

~~16.~~14. The use as claimed in claim ~~15~~13, wherein the autoimmune disease is selected from the group consisting of vitiligo, psoriasis, atopic dermatitis and eczema, lichen-planus, scleroderma, pemphigus, bullous, epidermolysis bullosa, systemic lupus erythematosus, dermatomyositis, and alopecia areata.

~~17.~~15. The use as claimed in claim ~~15~~13, wherein the subject has one or more depigmented skin areas, and the medicament is applied topically to at least one of the depigmented skin areas.

~~18.~~16. The use as claimed in claim ~~15~~13, wherein the treatment includes prophylactic and therapeutic treatments.

~~19.~~17. The use as claimed in claim ~~11~~9, wherein the ~~compound~~ medicament is to be used in combination or adjunctively with a second therapeutic agent.